Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

被引:27
|
作者
Kuwata, Hitoshi [1 ,2 ]
Yabe, Daisuke [1 ,3 ,4 ]
Murotani, Kenta [5 ]
Fujiwara, Yuuka [1 ]
Haraguchi, Takuya [1 ,2 ,3 ]
Kubota, Sodai [1 ,3 ]
Kubota-Okamoto, Saki [1 ,3 ]
Usui, Ryota [1 ,2 ]
Ishitobi, Minori [2 ]
Yamazaki, Yuji [1 ,2 ]
Hamamoto, Yoshiyuki [1 ,2 ]
Kurose, Takeshi [1 ,6 ]
Seino, Yusuke [7 ]
Yamada, Yuichiro [1 ,2 ]
Seino, Yutaka [1 ,2 ]
机构
[1] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Kobe, Hyogo, Japan
[2] Kansai Elect Power Hosp, Ctr Diabet Endocrinol & Metab, Osaka, Japan
[3] Gifu Univ, Grad Sch Med, Dept Diabet Endocrinol & Metab, Gifu, Japan
[4] Kobe Univ, Grad Sch Med, Div Mol & Metab Med, Kobe, Hyogo, Japan
[5] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan
[6] Nakanoshima Clin, Osaka, Japan
[7] Fujita Hlth Univ, Dept Endocrinol & Metab, Toyoake, Aichi, Japan
关键词
Gastric emptying; GLP-1 receptor agonist; islet hormones; OPEN-LABEL; INCRETIN SECRETION; LIRAGLUTIDE; LIXISENATIDE; GLP-1; STIMULATION; GLUCOSE; SAFETY; GIP;
D O I
10.1111/jdi.13598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. Materials and Methods A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. Results Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs. Conclusions All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
引用
收藏
页码:2162 / 2171
页数:10
相关论文
共 50 条
  • [31] Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
    Khan, Sadiya S.
    Ndumele, Chiadi E.
    Kazi, Dhruv S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2025, 333 (02): : 113 - 114
  • [32] Glucagon-like peptide-1 agonists
    Padwal, Raj
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [33] Glucagon-Like Peptide-1 Agonists
    Stanton, Eloise W.
    Manasyan, Artur
    Banerjee, Rakhi
    Hong, Kurt
    Koesters, Emma
    Daar, David A.
    ANNALS OF PLASTIC SURGERY, 2025, 94 (01) : 121 - 127
  • [34] Glucagon like peptide-1 receptor agonists in type 1 diabetes
    Deng, Chao
    Fan, Wenqi
    Li, Xia
    DIABETES & METABOLISM, 2023, 49 (06)
  • [35] Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists
    Jalleh, Ryan J.
    Jones, Karen L.
    Nauck, Michael
    Horowitz, Michael
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (11) : 1542 - 1543
  • [36] Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes
    Grosicki, Gregory J.
    Thomas, J. Graham
    Dhurandhar, Nikhil V.
    Lofton, Holly
    Heymsfield, Steven B.
    Jonnalagadda, Satya S.
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1597 - 1600
  • [37] Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
    Irfan, Huma
    Pallipamu, Namratha
    Farhat, Hadi
    Gutlapalli, Sai Dheeraj
    Thiagaraj, Suvedha S.
    Shukla, Twisha S.
    Venugopal, Sathish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [38] Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes
    Guo, Xueyuan
    Sang, Caihua
    Tang, Ribo
    Jiang, Chenxi
    Li, Songnan
    Liu, Nian
    Long, Deyong
    Du, Xin
    Dong, Jianzeng
    Ma, Changsheng
    DIABETES OBESITY & METABOLISM, 2023, 25 : 53 - 63
  • [39] The Role of Glucagon-Like Peptide-1 Agonists on Gastric Emptying Measured by Scintigraphy Imaging
    Kogilathotajagirdhar, Gowthami Sai
    Elmati, Praveen Reddy
    Qasba, Rakhtan
    Qasba, Ruman K.
    Perez, Andres Jose
    Hussain, Muhammad
    Shah, Mehul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1631 - S1631
  • [40] Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients
    Kim, Min Kyung
    Kim, Doo-Man
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (06) : 914 - 916